VC-backed Genocea Biosciences prices IPO – Fortune

According to Fortune, Genocea Biosciences has priced its IPO of 5.5 million shares at between $12 and $14 a share. The stock will trade on the NASDAQ under the ticker symbol “GNCA.” Citigroup and Cowen & Co. are the lead underwriters. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines. Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.

Leave a Reply

PE HUB Community

Join the 12515 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget